By 2010 Cell Based Markets Are Expected to Account for $56.2 Billion Which Will Continue to Increase to $96.3 Billion By 2015
Research and Markets (http://www.researchandmarkets.com/reports/c10806) has announced the addition of the Jain PharmaBiotech report: Cell Therapy – Technologies, Markets and Companies to their offering.
This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Cell therapy is bound to become a part of medical practice.
Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.
Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.
Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.
Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.
Collectively, the value of the cell-based markets was $26.6 billion in 2005, and is expected to increase to $56.2 billion in 2010, and $96.3 billion in 2015. The largest expansion will be in diseases of the central nervous system and cancer. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.
The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 200 of these are profiled in part II of the report along with tabulation of 136 alliances. Of these, 91 are involved in stem cell therapy. Important collaborations in the area of cell therapy are shown. The text is supplemented with 38 Tables and 10 Figures. The bibliography contains 500 selected refereces, which are cited in te text.
Topics Covered
0. Executive Summary
1. Introduction to Cell Therapy
2. Cell Therapy Technologies
3. Stem Cells
4. Clinical Applications of Cell Therapy
5. Cell Therapy for Cancer
6. Cell Therapy for Neurological Disorders
7. Ethical, Regulatory, and Safety Aspects of Cell Therapy
8. Markets and Future Prospects for Cell Therapy
9. References
Tables
Figures
For more information visit http://www.researchandmarkets.com/reports/c10806